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MULTIPLE MOUSE-PROTECTIVE ANTIBODIES DIRECTED
AGAINST GROUP B STREPTOCOCCI
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Streptococci for many years have been classified into a number of serological
groups, many of which have also been subdivided serologically into specific types
(1). It has been shown that these types, notably in Groups A and B, are related to
immunity of the host on the basis of the composition of their specific antigens
(2) .
In the case of Group B streptococci, a surprisingly high proportion of strains isolated
from both human and animal sources (references 3-12, and footnotes 1 and 2) could be
classifiedinto fourtypes-Ia, lb, II, and III-on thebasis of serological precipitin testswith
the specific capsular polysaccharides (Table I) . Subsequently, a number of strains were
encountered that reacted equally well with Type Ia and Type Ib type-specific antisera in
the diagnostic precipitin test (13). By specific absorption experiments it was confirmed
that these strains, provisionally designated as Type Ic, possess antigens in common, or
closely related to, antigens that occurregularly in strains ofType Ia on one hand and Type
Ib on the other (13) . The polysaccharide component isolated from these newly recognized
Type Ic strains was serologically indistinguishable from the hot HCl-extracted type-
specific polysaccharide of Type Ia strains and is the basis for the Ic cross-reaction with
Type Ia. A protein component common to Types Ib and Ic, designated Type Ibc protein
antigen,' is responsible for the cross-reaction with Type lb. No antigen with specificity
solely related to Type Ic strain was found, although it is possible that one may yet be
identified.
The immunology of the various Group B carbohydrate antigens has been the subject of
earlier studies reported from this and other laboratories (2-4, 3-16, 18, 19), and some
information has been obtained concerning the specific immunochemical determinants of
certain of these antigens. However, a detailed chemical analysis of these polysaccharides
with identification of each of the immunodominant components remains to be done. The
present evidence indicates that more than one specific determinant occurs in each of the
polysaccharides in its native form. Information concerning the protein antigens is meager.
Here again, the available evidence indicates that the Ibc protein possesses more than one
readily detectable specificity (13), but it has not been established whether this is referable
to two separate protein antigens or two determinants on a single molecule.
The experiments presented in the present paper were designed to determine
whether the protein antigens of Types Ib and Ic are significant in virulence and
* This study wassupported in part by the National Institutes of Health grant no. HL 03919 and a
grant from theNew York Heart Association.
'Lancefield, R. C. Unpublished data on Group B, Strain A909, 1966.
'Type nomenclature different in Stableforth's classification (5).
'Formerly designated Ic protein (13) .
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protection . Mouse-protection tests involving antibodies to polysaccharide anti-
gens have been previously reported (references 3, 4, 14, and 17 and footnote 1),
and these were extended as a background for the study of protective antibodies
directed specifically against the protein antigens. One of the interesting findings
emerging from these studies is that antibodies directed to either the polysaccha-
ride or the protein antigens of a single strain can be protective. Multiple
mouse-protective antibodies have been found in the sera of immunized animals
for all Group B types so far investigated. From one to three, or possibly four,
distinct antibodies may be found in a serum raised against a single type. By
absorption techniques, it can be shown that each antibody alone is capable of
passively protecting mice against experimental infection.
Materials and Methods
Streptococcal Strains. Representative strains of the specific types of Group B streptococci
employed previously (3) were used with the addition of a strain isolated from cultures of the
umbilicus in ahospital nurseryfornewborn infants. The strains used in the present report were: 090,
Type Ia; H36B, Type Ib; A909, Type Ic; 18RS21, Type II;D136C, Type III; and090R used to prepare
group-specific serum.
Mouse Passage.
￿
When a mouse-virulent derivative of a particular strain was required for the
passive protection tests used for antigen and antibody analysis, the organisms were passed serially
through mice .
The techniquewas as follows: 1 ml of fresh 16 h blood broth culture (or a larger dose if needed to
kill the mouse) was inoculated intraperitoneally into alargeadultmouse (26-28 g) . If the animal was
dead or moribund thenext day, it was autopsiedand the spleen removedaseptically to asmallsterile
mortar. Thespleen was ground sterilely with a pestle and takenup in a minimal amount of broth. 1
ml of suspension was inoculated into a mouse in the morning. If theanimal was sick by the endof the
afternoon, it was etherized and the spleen removed for further passage in another mouse overnight.
Smaller amounts of spleen suspension were passed twice daily into mice keeping the dose just large
enough to kill the mice in these passages. Inoculated mice were held at refrigerator temperature
overnight in order to reduce the danger of postmortem contamination of the spleen.
Sometimes a mouse-virulent organism (by mutation or selection during residence in the mouse)
wasobtained in afewpassages. Sometimesit was much more difficult or impossible to obtain such an
organism. The development of virulence was measured by a standard test using intraperitoneal
inoculation of serial dilutions of a broth subculture of the spleen suspension. Mouse passage was
continued untilthesubculture killed mice in a dose of 10-s-10-e ml. Thecultures were lyophilized or
stored at -60°C in enough tubes to supply a fresh sample for each day's work. Virulence tests on
cultures of related Type I types were performed in the manner shown in Table II.
Preparation of Antisera.
￿
New Zealand red or hare-brown rabbits weighing 8 to 10 lbs are used.
Several different methodsof treating thesuspensions forimmunizing with GroupBstreptococci have
been employed:
FOR TYPE-SPECIFIC ANTISERA.
￿
(a) The sediment of an overnight broth culture is killed by adding
3% formalin to the 20 times concentrated suspension to give a final concentration of 0.3% formalin.
The suspension is kept in the refrigerator at 4°C. Subcultures are usually sterile overnight.
Immunization schedule: A fresh 1:20 dilution in 0.85% NaCl solution is made each day, which
restores the suspension to the volume of the original culture. Injections of this dilution are made
intravenously into adultrabbits (8-101bs) as follows-1st wk: 0.5 ml for 3 successive days and 1.0 ml
for2successive days. 2ndwk: 1.0 ml for5 successive days and5days afterlast injection, test bleeding;
if unsatisfactory in precipitin test, continue injections. 3rd series: 1.0 ml for 5 successive days and 5
days later, test bleeding. 4th series (if necessary) : 1.0 ml for 5 successive days. 5 days later, test
bleeding. If unsatisfactory, rest animal for 1 mo.
Prepare fresh vaccine for booster series with 1:20 dilution for injection freshlyprepared daily. 1st
booster series:0.5 ml for3successive days and 1.0 ml for 2successive days;5days later, test bleeding.
2nd booster series: 1.0 ml for 5 successive days and 5 days later, test bleeding. If unsatisfactory,
rabbits may be discarded or rested for a month or more.R. C. LANCEFIELD, M. McCARTY, AND W. N. EVERLY
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Usually the serum is satisfactory much earlier. The final bleeding when the rabbit is exsan-
guinated must be individually tested for each rabbit to ascertain which of the possible antibodies
have been formed.
(b) A higher concentration of formalin (up to 3%) was unsatisfactory for preparing vaccines for
specific types of group B because type-specific polysaccharides are sometimes destroyed.
(c) Some rabbits were immunized with trypticor peptic digests of heat-killed vaccines to destroy
surface proteins which might interfere with the antigenicity of the polysaccharide type-specific
antigens. The results were somewhat indeterminate. Heat-killed vaccines (56°C/30 min) without
proteolytic digestion were also employed . Higher dosages of heat-killed organisms were used for
immunization in the same dosage as regularly used for group A strains (17) .
FOR GROUP-SPECIFIC ANTISERA.
￿
Strain 09011 which contains little or no type-specific antigen was
used either with 0.3% or with 3.0% formalin-killed cultures. This strain had been derived from the
Type la type-specific strain by dailyserial subculture in 10%type-specific antiserum in broth. Good
group-specific antisera were obtained. The R strain (09011), i.e. devoid of type-specific antigens,
tended to revert to the type-specific 090S form (containing type-specific antigens) under laboratory
conditions. Cultures were lyophilized or kept at -60°C to prevent reversion. It was necessary to
confirm frequently that the culture maintained the R form and to repeat subcultivation in type-
specific immune serum when indicated.
Specific Absorption of Antisera.
￿
Absorption was carried out with whole bacterial cells cen-
trifuged from broth cultures. These were usually heat-killed at 56°C for 30 minutes and used in a
proportion of 3parts of whole serum to 1part of packed cells. Some absorptions were carried out with
living cells. The preparations were mixed and incubated in a 37°C water bath for 0.5 h, then
centrifuged and theserumremovedand filtered through amilliporefilter. The sera were tested by the
precipitin and Ouchterlony techniques and in passive protection tests with mice.
This is essentially theimmunological method previously used in thetests to separate Types Ia and
Ib (4). Theuseof wholebacterialcells is asubstitute forabsorption with chemically purified antigens,
some of which have not been isolated and characterized. Effective depletion of certain antibodies
from whole serum required the undesirable procedure of repeated absorption. Better results could
probably be obtained by absorbingdiluted serum, but this wouldhave precludedtheuseofprecipitin
and double diffusion tests as controls.
Protection Tests.
￿
The mousewas considered the most suitable experimental animal available for
passive protection tests, becausein previous work immunity to human infection with streptococci was
well correlated with results of serum protection in mice.
In Group B, in contrast to Group A, protection obtained by simultaneous injection of culture and
serum is equally as good as that obtained by injecting the serum a day in advance of the culture. In
the studies with Group B streptococci, the titrations were carried out by injecting mixtures of the
virulent organism and theantiserum simultaneously, andeach serumdilution wastested in four mice
with several dilutions of the broth culture. Large and small doses of each component were usually
selected to cover the active ranges of both. In certain cases of doubt arising from erratic survival
patterns presumably due to differences in unknown factorsof host resistance, the test was repeated
with 10 replicate mice for each dose of serum and culture, a total of 40 mice in each case.
Most deaths of mice occurred in 1-2 days. Theexperiments were observed anddeaths recorded for
1 wk, or for longer if any mice did not appear well. The death of animals receiving absorbed serum
indicatedthe specific absorption of protective antibody. Survival of mice indicated that antibody was
left in the serum.
Experimental
Serological analysis of Group B; Types la, Ib, and Ic strains
The analysis of representative strains and rabbit antisera revealed a complex
pattern of antigenic composition reflected in corresponding antibodies. Previ-
ously the major type-specific polysaccharides which occur in Group B strepto-
cocci were referred to as "S" substances (soluble specific substances) in
conformity with usage for pneumococcus types (3). This designation is now
dropped for streptococci since other classes of substances have also been found168
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associated with specific type protection . By a combination of capillaryprecipitin,
gel double diffusion, and mouse-protective tests, the following picture emerges of
the major antigens involved in protection on which type designation is based:
Type Ia (Represented by Strain 090)
la, CARBOHYDRATE (Ia CHO) 4. la CHO, the major polysaccharide antigen.
(specific for Types la and le)
MINOR ANTIGEN .
￿
The minor antigen is probably a polysaccharide component
and a part of Ia CHO, which is common to all of the Type I-related types. Desig-
nated as labc cross-reactive antigen.
Type Ib (Represented by Strain H36B)
Ib CHO. Ib CHO, a major type-specific polysaccharide antigen (specific for
Type lb).
labc CROSS-REACTIVE ANTIGEN . Iabc cross-reactive antigen is probably a minor
determinant of Ib CHO.
A PROTEIN ANTIGENIC FRACTION.
￿
A protein antigenic fraction differentiated by
trypsin and pepsin sensitivities (13) . Designated Ibc protein and shared by Types
Ib and Ic . This may be composed of two serologically distinct reactants.
Type Ic (Represented by Strain A909)1
la CHO. la CHO, a polysaccharide closely related to la CHO of Type Ia strains.
Iabc. labc, minor determinantof polysaccharide.
Ibc PROTEIN . Ibc protein, a fraction similar to that found in Type lb. No
strictly Ic-specific antigen has been found.
This summary is presented as a guide for the interpretation of the detailed
experimental data which follow.
Mouse-Protective Antibodies Specific for theProteins of Types Ib and Ic
Mouse protection with antibodies reactive against the specific polysaccharide
immunodeterminants of Types la and Ib have been previously described. Special
attention is given here to the protein antigens Ibcwhich are present together with
the respective antigenic polysaccharides in Types Ib and Ic streptococci (Table
I) . A preliminary example of virulence tests of the strains used is given in Table
II.
In the early studies of Group B streptococci, in contrast to the pattern of
antigens in Group A, the antigenic structure seemed to be similar to that which
was well known for pneumococcus. In pneumococcus, serologically specific
polysaccharides were associated with protection for both man and mice .
The Group B streptococci were classified first by the precipitin test into types
designated I, II, and III on the basis of the specific polysaccharides which they
contained, with a certain number of strains unclassified. When several new sera
were employed, it was found that two specific related types showing cross-protec-
tion in mice occurred among Type I strains. Thesewere separated and designated
Types la and Ib . By studying antisera against each strain, the occurrence was
confirmed of specific types with varying amounts of cross-reactive antibodies in
'Abbreviation used in this paper: CHO, carbohydrate .Type
designation
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TABLE I
Summary of the Occurrence of Multiple Mouse-Protective Antibodies
against Group B Streptococci
'Designated Iabc polysaccharide (Table I) .
Mouse-protective antibodies against :
Polysaccharides*
Antigenic
Common protein
polysaccharide determinants
* The group-specific cell-wall polysaccharide does not give rise to protective antibodies.
$Mouse protection for these antigens not yet studied.
TABLE II
Example of Virulence Tests with Streptococcal Strains: Mouse-Passage Cultures
of Group B; Types Ia, Ib, and Ic
The number of streptococcal chains in the test culture was obtained by counting the numbers of
colonies in pour blood agar plates from each culture dilution employed.
* No. of mouse passages indicated after slanted line (/), e.g., 090/14.
$D, followed by a numeral indicates day of death.
§ S, indicates survival of a mouse for at least 1 week.
the antisera prepared. The cross-reacting antigen could not be separated from the
type-specific polysaccharide determinants . It appeared to be a nonprotein
serological determinant (Table I) common to the la and Ib strains (and later to
Type Ic strains.' The unabsorbed la and Ib antisera were often completely
type specific and devoid of cross-reactivity. Type-specific antisera could be
prepared by absorbing with any one of the three Type I-related strains in the
appropriate combination of serum and strain .
The third Type I-related type, designated Ic, contained the same polysaccha-
Strain 090/14, Strain H36B/60, Strain A909/14,
Virulencetitration* Type la Type Ib Type Ic
(no serumemployed;
0.2 ml culture dilutions) No. of Deaths No. of Deaths No. of Deaths
colonies colonies colonies
1:10-8 11 D2$ 9 D2 7 S§
1:10-' 57 Dl 38 D4 31 D2
1:10-6 247 D1 239 D1 217 DI
1:10-' D1 Dl Dl
Majorantigens
(specific)
determinant
(Iabc)
(cross-reactive)
(Ibc)
(cross-reactive)
Type la Is Present Absent
Type Ib Ib Present Present
Type Ic la Present Present
Type II II Absent $
Type III Hit Absent $170
ride antigen present in Type la, together with antigenic proteins not present in
Type la but closely similar to those in lb . This protein fraction was designated
Ibc to indicate the types in which it was found.
Table I is a summary of the information obtained in this and earlier work on
the occurrence of the antigens of Group B streptococci that induce mouse-protec-
tive antibodies. The experimental data which follow were selected from a large
number of mouse protection experiments using a variety of strains, antisera, and
reciprocal absorptions. The representative experiments presented (Table III)
serve to illustrate the finding that led to the current picture of mouse-protective
antibodies in the subtypes of Group B, Type I streptococci. This summary is
presented as a further guide for interpretation of the experimental data that
follow.
TABLE III
Guide for Sera Used in Analyzing the Occurrence of Multiple Mouse-Protective Antibodies
against Group B Streptococci
MULTIPLE MOUSE-PROTECTIVE ANTIBODIES
For virulence of streptococcal strains used in these studies, see Table II.
* This serum was selected as an example ofantiserum having protective antibodies directed only to the Iabc determinant.
Antisera to strain A909 (Ic) usually contain antibodies to both the la CHO and Ibc Protein.
Mouse Protection with Antisera Containing Ibc Antibodies
A Type Ib antiserum (no. 52) was selected which did not show cross-protection
with Type la streptococci in order to avoid the complication of the Iabc
cross-reaction (Tables I and III) . Response of individual rabbits to the same
antigen varies . This rabbit (W3192) had been immunized with a Type Ib strain
(C12B) and represented one of the variations in response of rabbits to
immunization with the same vaccine. The unabsorbed serum (no. 52, Table IV)
contained streptococcal antibodies Ibc corresponding to antigens in both Type lb
and Type Ic organisms. After four repeated absorptions with living or heat-killed
culture of either Ib or Ic streptococci, the mouse-protective antibodies referable
to the immunodeterminants Ibc were absorbed by either strain. This was shown
even when the absorbed serum samples were tested with 10 replicate mice for
each dose of absorbed serum (Table IV A, samples no. 52R or no . 52N) . It was
concluded that the The antibodies had been absorbed specifically by strain A909
Serum designation Mouse-protective antibodies
againstinvolved antigens
Strains used
for Is major Ib major Iabc Ibc
Type Code Rabbit immunization CHO CHO common antigenic
(specific) (speck) CHO protein
determinant determinant
Type Ia 26 (Table V) W3178 Strain 090 (Ia), Present Absent Absent Absent
formalin killed
Type Ib 52 (Table IV W3192 Strain C12B (lb), Absent Present Absent Present
andIV A) formalin killed
Type Ib 13 (Table W3835 Strain H36B (Ib), Absent Present Absent Present
VI) tryptic digest
vaccine
TypeIb 20 (Table W3181 Strain H36B (lb), Absent* Present Present Present
VII) formalin killed
Common CHO 22* (Table W3224 Strain AA909 (le) Absent* Absent Present Absent*
(Iabc) VIII)R. C. LANCEFIELD, M . McCARTY, AND W . N. EVERLY
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(sample no. 52N), and also by strain H36B (sample no. 5211) which contained Ibc
protein antigen as well as Ib type-specific polysaccharide. Serum sample no.
52N, however, still contained mouse-protective antibodies effective against the
type-specific Ib polysaccharide determinant. This protective property was re-
moved only if a Ib strain (H36B) containing the Ib CHO determinant were the
absorbing agent (sample no. 5211). When, however, strain A909, the Ic strain
which did not contain the Ib CHO was the absorbing agent (sample no. 52N), the
antibodies to the Ib polysaccharide remained in the serum and protected mice
against strain H36B. Only those to the The proteins were absorbed from this
sample by strain A909, thus showing their relationship to the Ic strain A909.
Table IV shows that absorption of serum no. 52 with Ib strain H36B removed anti-
bodies protective for both Types Ib and Ic (no. 5211). Strain A909 (Type Ic) ab-
sorbed Type Ic protective antibodies (no. 52N) but the same absorbed serum
still protected against infection with strain H36B (Type Ib).
In serum sample no. 5211 absorbed with theIb strain H36B it wasobserved that
the strain containing the major type-specific polysaccharide (H36B) was slower
in removing Ibc antibody than the Ic strain A909, possibly due to steric hin-
drances between the polysaccharide and protein antigenic determinants in Type
Ic or the competitive absorption of antibody to antigens in the cell surface. Pre-
cipitin tests both in capillary tube and agar gel techniques supported the conclu-
sions of the serological similarity of these protein determinants in the two types.
It was concluded from the results of this and similar experiments that separate
antibodies to specific polysaccharides and antigenic protein immunodetermi-
nants existed in the same serum after immunization with a single strain. Mouse
protection was brought about by either kind of antibody specificity, The protein
as well as specificity due to the polysaccharides la or lb, in response to strains
containing the corresponding antigenic determinant.
Re-Examination of Mouse Protection with Antibodies to Specific Poly-
saccharides of Individual Types
Types Ia and Ic: The Major Specific Polysaccharide, Ia CHO.
￿
To furnish a
background for the studies described of mouse protection with Ibc antibodies
against Group B streptococci containing Ibc protein antigens, protective anti-
bodies directed against polysaccharide immunodeterminants have been re-
examined for several specific types within Group B. These polysaccharides
appear to be the major type-specific antigens (Tables I and III) . They are
characterized by a high degree of immunological activity. Passive protection of
mice by means of dilutions of antiserum to 1:10,000 or more is not unusual. A
dilution of 1:80,000 has been effective with some sera. An example (Table V) is
shown of a Type la serum which protects both la and Ic strains. Both strains
contain the la polysaccharide and mice are protected against either strain at a
serum dilution of at least 1:4,000. This serum affords no protection to a strain of
heterologous Type Ib (H36B) which does not contain Ia type-specific polysaccha-
ride, and none to other heterologous types (Type II).
Either strain 090 (Type la) or strain A909 (Ic) absorbs all protective antibody
from this serum in suitable absorption experiments which have been performed
but are not recorded here.172 MULTIPLE MOUSE-PROTECTIVE ANTIBODIES
TABLE IV
Absorption of Type Ib Antiserum: Example to Show Mouse Protection with
Antibodies Directed to Ibc Proteins
Serumno. 52
(against lb strain)
absorption record
Challenge strains
(1 mouse challenged with each dose
of serum and culture;
culture dilution 10-3)*
Interpretation of
content of relevant
antibodies before
and after absorp-
tion of no. 52 serum
sample resulting
in protection of
mice
Unabsorbed antiserum
contains antibodies
to (a) type-specific
Ib CHO, and (b) pro-
tein Ibc. See Table III.
Nosignificant anti-
bodies left in no. 52R
after absorption with
Ib strain. See Table
IV A
Antitype-specific
Ib CHO leftin no. 52N
after absorption with
Ic strain.Protects
homologous type strain
0.2 ml of serum dilutions plus 0.2 cc of 10- ' dilution of culture (10-° of culture dilution tested but not plotted
here) . See Table IV A for continuation ofrecord with certain criticalcombinationsof serum and culture challenged
with 10 mice each for confirmatory tests of absorption of antibodies. Absorption of serum no. 52 with Type Is,
(strain 090) was performed as above. Results were not tabulated here. Four repeated absorptions did not remove
the Ibc antibodies since la strains do not contain the protein Ibc antigen.
* See Materials and Methods and Tables 1, II, and III.
Type Ib: Major Specific Polysaccharide, Ib CHO.
￿
Using an example ofType
Ib antiserum (Table VI) which does not have cross-reactivity due to the common
polysaccharide determinant Iabc, specific protection directed to the Ib polysac-
charide can be demonstrated . This has been confirmed in appropriate cross-
absorption experiments (Tables IV, IV A, andVII). A complication is encountered
because antibody against the Ibc protein has also been induced in this serum
(serum no. 13, Table VI) by the Ib strain, as is customary with rabbits
immunized with strains of this type. Table VI illustrates protection obtained
when this Ib serum is tested unabsorbed against the three strains in question. It
does not protect mice against infection with the Type la strain because no Iabc
antibody is present. However, this serum protects mice against the homologous
Ib strain with one orboth Ib antibodies which are present, anti-Ib polysaccharide
or anti-Ibc protein. The unabsorbed Ib antiserum also protects mice against the
heterologous strain A909 because ofthe anti-Ibc antibodies present. Similar selec-
tive absorption of this serum, not recorded here, confirms this.
Another of the cross-absorption experiments to confirm the specific protection
Serum sample
treatment and
designation
Serum
dilution
090/14,
Typela
H3613/60,
Type Ib
A909/14,
Type Ic
Unabsorbed*; no.52 1:50 D1 S S
1:1,000 DI S S
Interpretation of Protected by Protected
protection anti-Ib CHO by anti-
and by anti- The pro-
Ibc protein tein
Absorbed 4 times with 1:50 D1 D1 S
Type Ib, Strain 1:1,000 D1 D1 D2
H36B;no.52R
Interpretation of Slight or
protection none
Absorbed 4 times with 1:50 D1 S DI
Type Ic Strain 1:1,000 D1 S D2
A909; no. 52N
Interpretation of Protected by
protection anti-Ib CHOR. C. LANCEFIELD, M . McCARTY, AND W. N . EVERLY
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TABLE IV A
Confirmatory tests of absorption of Ibc antibodies
See Materials and Methods. 0.2 ml of serum dilutions plus 0.2 ml of 10- ' dilution of culture injected into each
mouse. 10- dilution of culture tested with same results.
directed against the Type Ib-type polysaccharide is shown in Table VII. This
serum (no. 20) contains three separate protective antibodies demonstrable by
selective absorption (see guide for sera analyzed, Table III). Suffice it to say that
examination ofthe data recorded in Table VII shows that after suitable selective
absorption the serum (no. 20d) protects specifically against Type Ib, and not
against Types la and Ic. The same result is seen throughout Group B experiments
but is not tabulated here. Type-specific protection can be obtained by absorbing
the Type Ib unabsorbed serum shown in Table VI. Absorption with strain A909
(Ic) removes antibody directed against the Ibc antigen but does not absorb the
protective antibody against Ib CHO. Strain H36B (Ib) is still protected.
Chemical studies ofthe responsible type-specific polysaccharides, Ia CHO and
Ib CHO, were previously reported (4, 13, 19) and have not been repeated in these
experiments.
Mouse-Protective Antibody with Specificity for the Polysaccharide De-
terminant (Iabc) Common to Three Types; Types la, Ib, and Ic
Another protective antibody can be demonstrated which is common to Types
la, Ib, and Ic (3). The antigen is designated temporarily Iabc to indicate the types
involved. Antibodies have been induced with representatives of all three ofthese
types, and sera have been obtained in each case in which the protective
properties appear the same for all of them. An example is shown in Table VIII
(serum no. 22). Any one of the three Type I-related strains absorbs all antibody
for the common polysaccharide determinant. The nature of this common
Treatment and
designation
Serum
dilution
H36B/60, Type lb
Mice Mice
survived died
A909/14, Type Ic
Mice Mice
survived died
in strains used
Absorbed 4 times 1:50 4 6 4 6 Strain H36B contains
with Type Ib, 1:1,000 1 9 0 10 type-specific antigen
Strain H36B; Ib CHO and protein
no. 52R antigen Ibc (probably
coveredby major
antigen Ib CHO)
Interpretation Partial absorption Partial absorption
ofprotection ofAnti-Ib CHO of Anti-Ibc
protein
Absorbed 4 times 1:50 10 0 0 10 Strain A909 contains
with Type Ic, 1 :1,000 10 0 1 9 protein antigen Ibc
Strain A909; butnot polysaccharide
no. 52N antigenIb CHO
Interpretation Protected by anti- Probably complete
of protection Ib CHO absorption ofanti-
Ibc (possibly trace
ofanti-Iabc)
Serum no. 52 Challenge strains
(against Ib strain) (10 micechallenged with each dose
absorption record of serum and culture;
culture dilution 10- ') Commenton
relevant antigens174
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TABLE V
Type Ia Unabsorbed Antiserum: Mouse-Protection Tests in Related Types Ia, Ib, Ic;
Example of Serum with MajorIa CHO Antibody
See Materials and Methods and Table III. 0.2 ml of serum dilution plus 0.2 ml of 10-6 dilution of
culture injected into each mouse. No crossreaction with TypesII andIII. This serumdoes not contain
antibodies to Iabc common determinant. Allanti-la CHO antibodies can be absorbed with either la
or Ic strains.
TABLE VI
Type Ib Unabsorbed Antiserum Mouse Protection Tests in Related TypesIa, Ib,and Ic;
Exampleof Serum with Ib Antibodies (Anti-Ib CHO, andanti-Ibc Protein)
Serum no. 13
(against strain
H36B), Type Ib
serum
Challenge strains
090/14,Type la
￿
H36B33, Type Ib
￿
A909/14, Type Ic
Interpretation
￿
No protection
￿
Protectedby anti-Ib
￿
Protected by anti-Ibc
ofprotection
￿
CHO andanti-Ibc
￿
protein
protein
See Methods and Table III. 0.2 ml of serum dilution plus 0.2 ml of the culture dilution injected into
each mouse.
antigenic determinant is not known, but the evidence indicates that it occurs in
the capsular polysaccharide. It is characterized as a minor determinant because
it appears to induce antibody less commonly and in smaller amount than the
major determinants of the two polysaccharides (Ia and Ib). Detailed immuno-
dilutions
10-1 10-' 10-6 10-' 10 -2
Culture
10-'
dilutions
10-6 10-' 10-2 10-3 10 -6 10-7
1:1 D1 D2 D2 S S S S S S S S S
1:10 Dl D1 D2 D2 S S S S S S S S
1:100 D1 D6 D6 DI S S S S D1 S D6 S
1:1,000 Dl D1 DI Dl D2 S S S D1 D1 S S
1:10,000 D1 Dl Dl D2 D2 D2 S D6 Dl Dl D2 S
Serum no. 26
(against strain 090),
Type la serumdilutions
Challenge
090/14, Type la
strains, culture
Type
Ib
lb'
dilutions 10- e
A909/14, Type Ic
1:1 S Dl S
1:10 S D1 S
1:1,000 S Dl S
1:2,000 S DI S
1:4,000 S Dl S
1:10,000 D1 Dl Dl
1:20,000 D1 D1 Dl
Interpretation of Protectedby Protected by
protection anti-la CHO anti-laCHOTABLE VII
Absorption of Type Ib Antiserum Mouse Protection Tests; Example of Type-Specific Antibody
(Anti-Ib CHO not Absorbed by Ibc Protein in Absorbent)
Serum no. 20 (against strain H36B),
Type Ib absorption record
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Challenge strains
Complete absorptionofanti-Ibc
Incomplete absorp-
￿
No protection
tion of anti-Ib CHO
which protects
0.2 ml of serum dilution plus 0.2 ml of culture dilution injected into each mouse. This serum is also
illustrative of immunology of Iabc and Ibc antigens and antibodies. Sample no. 20d illustrates complete
absorption of anti-Ibc from Ib antiserum without removing type-specific anti-Ib CHO. Compare with
titration of these antibodies in Table VI.
* See Methobs and Tables III and VI.
$ Probably a variation of host resistance in single mouse.
chemical studies of these antigens are needed for precise identification of the
determinants .
It is obvious that these results merely begin to uncover the intricacies of this
problem. It is strongly indicated from these experiments that separable protec-
tive antibodies to several bacterial determinants, both polysaccharide and
protein, exist and are reflected in a single serum with cross-relationships between
strains and types. Any one of these diverse antibodies appears capable alone of
protecting challenged mice from becoming infected with a strain containing any
one of the corresponding antigens which induce the antibody specific for that
antigen.
Further work on the results of quantitative comparisons is indicated to eval-
uate this complicated series of immunological reactions. The solution of these in-
Serum sample
treatment anddesignation
Serum
dilution 090/14, Type Is
10-1 10-1
H36B/60, Type Ib
Culture dilutions
10-3 10-1
A909/14, Type Ic
10-' 10-1
Unabsorbed*; no. 20 1:50 S S S S S S
1:1,000 Dl S S S S S
Interpretation ofprotection Protected by Protected by Protected by
anti-Iabc anti-Ib CHO,
anti-Iabc, and anti-Ibc
anti-Ibc
Absorbed 1 time with Type Is, 1:50 D1 Dl S S S S
090/14; no. 20a 1:1,000 Dl DI S S S S
Interpretation of protection Noprotection Protectedby Protectedby
(anti-Iabc absorbed) anti-Ib CHO anti-Ibc
and anti-Ibc
Absorbed 1 time with Type Ic, 1:50 Dl D2 S S S S
A909/14; no. 20c 1:1,000 Dl Dl S S S S
Interpretation ofprotection No protection Protected by Protected by
(anti-Iabc absorbed) anti-Ib CHO anti-Ibc,
with or without absorption
anti-Ibc incomplete
(Sample no. 20c absorbed 1:50 Dl Dl S S Dl D2
1 time withType lb, H36B)
No. 20d 1:1,000 Dl D1 S D2$ Dl Dl
Interpretation ofprotection No protection176
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TABLE VIII
Type Ic Unabsorbed Antiserum Mouse-Protection Tests in Related Types Ia, Ib, and Ic;
Example of Serum with Iabc Antibodies
Serumno. 22
(against strain A909),
Type Ic
serum dilutions
Challenge strains, culture dilutions 10-3
090/14, Type la
￿
H36B/60, Type Ib
￿
A909/14, Type Ic
1:50
￿
S
￿
S
￿
S
1:1,000
￿
S
￿
S
￿
S
1:2,000
￿
D6
￿
S
￿
S
1:4,000
￿
D4
￿
S
￿
S
1:8,000
￿
D5
￿
D1
￿
S
1:16,000
￿
D5
￿
D1
￿
D5
Interpretation
￿
Protected by
￿
Protected by
￿
Protected by
ofprotection
￿
anti-Iabc
￿
anti-Iabc
￿
anti-Iabc
See Methods andTable III. 0.2 ml of serum dilution plus 0.2 ml of culture dilution injected into each
mouse. Type Ic antisera-containing antibodies (anti-la, anti-Iabc, and anti-Ibc) in all various
combinations occur and have been analyzed: no strictly Ic-specific antigen has been found. All
antibodies (Iabc) can be absorbed from this serum with any one of the three challenge strains .
terrelationships would aid an understanding of the infective properties of these
organisms.
Discussion
The investigation of the immunological importance of the protein antigen Ibc
led to re-examination of other type-related antigens in Group B found previously
to induce specific mouse-protective antibodies . In the study of any newly
identified antigen in bacterial species connected with immunity, it is essential to
establish its composition and structure, and to ascertain its relationship to
infection and resistance. In investigations focused on human or other animal
infections, it is not enough to show that antigens fulfill the usual criteria of
inducing and reacting with antibodies. A biological animal test of immunity is
requisite. Procedures for defining identity or partial relationship of strains or
individual antigens have included reciprocal absorption of sera with whole or
treated bacteria and subsequent testing of each supernatent by mouse protec-
tion. Usually in immunological studies of protective antibodies, specific polysac-
charides or proteins have been the basis for establishing individual types among
the gram-positive cocci which could then be confirmed by mouse protection . The
protective antibodies for types have usually been limited in these bacteria to a
single antigenic component among the many occurring in the specific types
investigated. The specific type designation has corresponded to this antigen. In
the present example more than one specific antigen capable of inducing mouse
protective antibodies has been encountered in several types.
In a study of the immunological importance of an antigen, it is preferable to
use chemically purified antigens derived from the type strains, with the results
evaluated by means of protection tests in experiments paralleling the quantita-
tive precipitin analysis. Since purified preparations were not availablefor most ofR. C. LANCEFIELD, M. Me CARTY, AND W. N. EVERLY
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the Group B streptococcal antigens, the earlier standard immunological absorp-
tion techniques with whole bacteria were employed to demonstrate the impor-
tance of the newly encountered Ibc proteins in infection and immunity. It was
much more difficult to interpret the value of the antigenic components in the
present experiments where Type Ic was involved than in the earlier studies with
Types la and lb. This may have been due to the larger number and varying con-
centrations of antigen-antibody systems involved, to the chemical or spatial ar-
rangements of the antigens in the cell, or to otherunknown factors, such as stabil-
ity of the antigens or competitive binding of antibodies to the surface of cells.
These factors remain to be elucidated.
A provisional type designation depending upon differences in specific mouse-
protection tests was made for Type Ic with a view to accounting for cross-protec-
tion results. The new type, Ic, was clearly different by the mouse-protection test
from either of the established types, la or Ib, both of which cross-reacted strongly
with Type Ic in protection experiments. Studies of this type have so far not
demonstrated a specific antigen to correspond solely to Type Ic either by
serological or by other biological-testing methods.
It was thought that a combination of the cross-protective antibodies found
might be sufficient to account for all the type-related protection of Type Ic which
gave cross-reactions with both la and Ib . The mouse-protection experiments with
Ic antisera absorbed with various combinations of the cross-reacting strains of
these types have, however, been indecisive in some experiments as to whether
there remained a protective antibody after complete absorption of Ic antiserum
with all of the known antigens involved. No suggestion has been found of the
nature of such a hypothetical unknown antigen, although it may be recalled that
a type-specific sialic acid immunodeterminant was demonstrated in previous
studies with Type II after absorption was complete with other type-specific
antigens . The uncertainty about any additional antigen in Ic may be due to the
chemical lability of such a substance or to confusion caused by the high dilutions
in which several known Group B type-related antibodies are protective.
Alternatively, no such antigen may exist.
The antibodies in Ic antisera which are known to be mouse-protective are
summarized in Table I. Those specific for the The proteins were demonstrably
mouse-protective whether induced in response to Ib or Ic strains, provided the
immunizing strains carried the Ibc protein determinants. These results demon-
strated that in the absence of the known polysaccharide-type antigens the
protein antigenic determinants, Ibc, were capable of eliciting protective anti-
bodies against passive infection in mice with strains containing this protein. The
necessity and value of further studies of this component of Group B streptococci
were therefore evident.
In previous work on the protective antigen-antibody systems of Type II, dual
immunodeterminant antigens had been found occurring in the type-specific
substance in the same strain. This finding led to the discovery of two distinct
antibodies both directed specifically against Type II. Chemically these antigens
were shown to consist of a heat- and acid-stable polysaccharide separable from
the native whole antigenic polysaccharide which does contain a labile im-
munodeterminant, an antigenic sialic acid (18) . Both these components contrib-178
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uted to the whole antigen. The possible existence of similar specific constituents
of the other known types requires further study. Complete mouse protection
studieshave notso far been made with Type III.
Summary
The data presented in this paper establish the finding that multiple specific
protective antibodies exist in rabbits in response to immunization with Group B
streptococci. The summary in Table I indicates the serological types into which
Group B streptococci have been divided on the basis of their antigenic
composition. This classification is dependent upon passive protection of mice
with antibodies directed against the specific antigens, and types are defined in
these terms.
Heretofore, it was thought that type-specific polysaccharides accounted for all
such protection in Group B streptococci. Certain exceptions of cross-protection
between types due to minor polysaccharide determinants soon appeared;
cross-protection reactions based on protein determinants in at least two types
were also discovered. The present experiments show that specific antibodies
directed to either polysaccharide or protein antigens of a single strain can be
protective against infection with streptococci containing these antigens.
Received for publication 17 March 1975.
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